Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention | Zendy

Pierluigi Tricoci | Zendy; Jennifer Vergara-Jimenez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Author(s) -

Pierluigi Tricoci,

Jennifer Vergara-Jimenez

Publication year - 2010

Publication title -

vascular health and risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.892

H-Index - 68

eISSN - 1178-2048

pISSN - 1176-6344

DOI - 10.2147/vhrm.s4168

Subject(s) - abciximab , medicine , conventional pci , percutaneous coronary intervention , myocardial infarction , antithrombotic , cardiology , randomized controlled trial , platelet aggregation inhibitor , clinical trial , intensive care medicine , aspirin

Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research